Abstract

PurposeStudies on unresectable colorectal cancer liver metastasis(CRLM) rarely analyze the prognosis of the patients from the point of colonic subsites. We aimed to evaluate the effect of primary tumor resection (PTR) and different scope of colectomy on the prognosis of patients with unresectable transverse colon cancer liver metastasis (UTCLM), hepatic flexure cancer liver metastasis (UHFLM), and splenic flexure cancer liver metastasis (USFLM).Patients and methodsThe patients were identified from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015. Cox proportional hazards regression models were used to identify prognostic factors of overall survival (OS) and cause-specific survival (CSS). Kaplan-Meier analyses and log-rank tests were conducted to assess the effectiveness of PTR on survival.ResultsIn total, this study included a cohort of 1960 patients: 556 cases of UHFLM, 1008 cases of UTCLM, and 396 cases of USFLM. The median survival time of whole patients was 11.0 months, ranging from 7.0 months for UHFLM patients to 15.0 months for USFLM patients. USFLM patients had the best OS and CSS, followed by UTCLM patients. UHFLM patients had the worst OS and CSS (All P < 0.001). PTR could improve the OS and CSS of UTCLM, UHFLM, and USFLM (All P < 0.001). Subgroups analysis revealed that USFLM patients with tumor size≤5 cm and negative CEA had not demonstrated an improved OS and CSS after PTR. Multivariate analysis showed that PTR and perioperative chemotherapy were common independent prognostic factors for UHFLM, UTCLM, and USFLM patients. There was no difference between segmental colon resection and larger colon resection on CSS of UHFLM, UTCLM, and USFLM patients.ConclusionsWe confirmed the different survival of patients with UTCLM, UHFLM, and USFLM, and for the first time, we proved that PTR could provide survival benefits for patients with unresectable CRLM from the perspective of colonic subsites of transverse colon, hepatic flexure, and splenic flexure. Besides, PTR may not improve the prognosis of USFLM patients with CEA- negative or tumor size≤5 cm. For oncologic outcomes, we concluded that segmental colon resection seemed an effective surgical procedure for UTCLM, UHFLM, and USFLM.

Highlights

  • Colorectal cancer (CRC) is one of the most common cancers with the second-highest morbidity in men and women and the second leading cause of cancer-related death worldwide

  • We confirmed the different survival of patients with unresectable transverse colon cancer liver metastasis (UTCLM), unresectable hepatic flexure cancer liver metastasis (UHFLM), and unresectable splenic flexure cancer liver metastasis (USFLM), and for the first time, we proved that primary tumor resection (PTR) could provide survival benefits for patients with unresectable cancer liver metastasis (CRLM) from the perspective of colonic subsites of transverse colon, hepatic flexure, and splenic flexure

  • PTR may not improve the prognosis of USFLM patients with carcinoembryonic antigen (CEA)- negative or tumor size≤5 cm

Read more

Summary

Introduction

Colorectal cancer (CRC) is one of the most common cancers with the second-highest morbidity in men and women and the second leading cause of cancer-related death worldwide. The ideal surgical treatment for patients with colorectal cancer liver metastasis (CRLM) seems to be complete surgical resection of liver metastases at the time of primary tumor resection (PTR). At the time of diagnosis, 75–90% of CRC patients are unable to undergo surgical resection because of liver metastasis [12]. For these patients with unresectable CRLM, the guidelines of the National Comprehensive Cancer Network (NCCN) do not recommend PTR unless there is obstruction, acute bleeding, or perforation [13]. Growing evidence has shown that PTR could prolong the survival of patients with unresectable CRLM [14,15,16,17]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call